Serum CA125 is a novel predictive marker for pancreatic cancer metastasis and correlates with the metastasis-associated burden
Serum CA125 is a novel predictive marker for pancreatic cancer metastasis and correlates with the metastasis-associated burden
复制标题
血清 CA125 是胰腺癌转移的新型预测标志物，与转移相关负担相关
DOI：
10.18632/oncotarget.6819
复制
发表时间：
2016-02-02
期刊：
影响因子：
--
通讯作者：
Yu, Xian-Jun
中科院分区：
文献类型：
--
作者：
Liu, Liang;Xu, Hua-Xiang;Yu, Xian-Jun
本研究评估了血清肿瘤标志物预测胰腺癌转移的发生率和强度以及患者生存率的潜力。从两个高容量机构收集了905例患者的回顾性记录和142例患者的前瞻性数据。分析消化道肿瘤常用的8种肿瘤标志物（CA 19 -9、CEA、CA 242、CA 72 -4、CA 50、CA 125、CA 153和AFP）在胰腺癌各期的水平。血清CA 125水平与胰腺癌转移的相关性最强，并且在转移性疾病患者中高于无转移性疾病患者。CA 125水平随着淋巴结转移和远处器官转移的增加而增加，尤其是肝脏。高基线CA 125水平预测胰腺切除术后早期远处转移，并与术前存在隐匿性转移有关。确定最佳CA 125临界值为18.4 U/mL;基线CA 125水平为18.4 U/mL或更高的患者手术结局较差。此外，高血清CA 125水平与转移相关基因标签的表达以及与胰腺癌转移相关的“驱动”基因表达的改变相一致。因此，CA 125可能是一个有前途的，非侵入性的，转移相关的生物标志物，用于监测胰腺癌预后。
This study evaluated potential of serum tumor markers to predict the incidence and intensity of pancreatic cancer metastasis as well as patient survival. Retrospective records from 905 patients and prospective data from 142 patients were collected from two high-volume institutions. The levels of eight serum tumor markers (CA19-9, CEA, CA242, CA72-4, CA50, CA125, CA153, and AFP) commonly used in gastroenterological cancer were analyzed in all stages of pancreatic cancer. Serum CA125 levels were the most strongly associated with pancreatic cancer metastasis and were higher in patients with metastatic disease than those without. CA125 levels increased with increasing metastasis to lymph nodes and distant organs, especially the liver. High baseline CA125 levels predicted early distant metastasis after pancreatectomy and were associated with the presence of occult metastasis before surgery. An optimal CA125 cut-off value of 18.4 U/mL was identified; patients with baseline CA125 levels of 18.4 U/mL or higher had poor surgical outcomes. In addition, high serum CA125 levels coincided with the expression of a metastasis-associated gene signature and with alterations in “driver” gene expression involved in pancreatic cancer metastasis. CA125 may therefore be a promising, noninvasive, metastasis-associated biomarker for monitoring pancreatic cancer prognosis.